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Abstract
Introduction—Bisphosphonates are highly effective in reducing fracture risk yet some 
individuals treated with these agents still experience fracture. The goal of this study was to test the 
hypothesis that genotype influences the effect of zoledronate on bone mechanical properties.
Methods—Skeletally mature male mice from genetic backgrounds known to have distinct 
baseline post-yield properties (C57/B6, high post-yield displacement; A/J, low post-yield 
displacement) were treated for 8 weeks with saline (VEH) or zoledronate (ZOL, 0.06 mg/kg 
subcutaneously once every four weeks) in a 2×2 study design. Ex vivo µCT and mechanical testing 
(4-pt bending) were conducted on the femur to assess morphological and mechanical differences.
Results—Significant drug and/or genotype effects were found for several mechanical properties 
and significant drug × genotype interactions were found for measures of strength (ultimate force) 
and brittleness (total displacement, strain to failure). Treatment with ZOL affected bone 
biomechanical measures of brittleness (total displacement (−25%) and strain to failure (−23%)) in 
B6 mice significantly differently than in A/J mice. This was driven by unique drug × genotype 
effects on bone geometry in B6 animals yet likely also reflected changes to the tissue properties.
Conclusion—These data may support the concept that properties of the bone geometry and/or 
tissue at the time of treatment initiation play a role in determining the bone’s mechanical response 
to zoledronate treatment.
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INTRODUCTION
Bisphosphonates have consistently been shown to be highly effective in reducing fracture 
risk [1]. While the majority of individuals experience the anti-fracture benefits of 
bisphosphonate treatment there is a small population of patients that fail to respond to 
treatment, defined as either not increasing BMD or experiencing a fracture [2–8]. Gaining a 
greater understanding of individual variation of response to drug treatment may lead to a 
more personalized treatment approach for fracture risk reduction.
Bone morphology and material properties exhibit great heterogeneity across the human 
population [9, 10]. Based on similar heterogeneity across genetic mouse strains [11–13], it 
has become clear that interactions between bone morphology and material properties (i.e. 
mineralization, remodeling, etc.) determine a bone’s mechanical properties. At far ends of 
the spectrum are bones referred to as slender – those with narrow widths relative to the 
length – and other referred to as robust – those with large widths relative to length. Slender 
bones (typical of some genetic mouse strains such as A/J) have higher cortical thickness, 
lower cross-sectional area moments of inertia, higher mineralization and lower remodeling – 
culminating in stiffer bones but with relatively lower post-yield behavior (i.e., brittle) [13]. 
Robust bones (typical of other genetic mouse strains such as B6) have lower cortical 
thickness, higher cross-sectional area moments of inertia, lower mineralization, and higher 
remodeling – culminating in a comparable whole bone stiffness as the slender mice but with 
relatively higher post-yield behavior (i.e., ductile)[13]. Despite significant work to 
understand interactions among morphological and material property traits, surprisingly little 
has been done to understand how these interactions affect the response to bone targeting 
drug treatments.
Bisphosphonates have well-described effects on bone remodeling, affecting bone 
morphology, mineralization, and mechanical properties [14]. Alterations in mechanical 
properties tend to manifest as improvements in ultimate force and stiffness, at the expense of 
reduced post-yield properties at the structural and/or material level [14]. In this study we 
aimed to test the hypothesis that the mechanical effects of zoledronate, one of several 
bisphosphonates used clinically, differ between inbred strains of mice that have divergent 
morphologies/mechanical properties (robust versus slender).
METHODS
Animals and bisphosphonate treatment
Prior to initiating these studies, all procedures were approved by the Indiana University 
School of Medicine Animal Care and Use Committee. Two strains of male mice were used 
in this study: C57Bl/6J (mouse strain with robust bones, n=40) and A/J (mouse strain with 
slender bones, n=40). Male mice were chosen as the majority of previous work in these 
strains used males [11–13]. Animals received a single injection of zoledronic acid (ZOL, 
subcutaneous injection of 0.06 mg/kg/BW, n=20/strain) or saline vehicle (VEH, n=20/strain) 
at 16 weeks of age, then another at 20 weeks of age. Treatment initiation at 16 weeks was 
based on the idea that skeletal growth has slowed by this age. The dose and duration of ZOL 
was chosen as it has shown efficacy in suppressing remodeling in mice [15]. At 24 weeks of 
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age, animals were euthanized and femurs were removed, wrapped in saline-soaked gauze, 
and frozen. Four of the bones were damaged during dissection and thus not available for 
analysis.
µCT Imaging
Femora were scanned (Skyscan 1176, 9 micron resolution) prior to mechanical testing to 
obtain trabecular morphology (trabecular bone volume) of the distal femur (0.5 mm long 
segment of the metaphysis region) and the cortical geometry at mid-diaphysis (single slice 
ROI). Trabecular parameters included bone volume, tissue volume and bone volume/tissue 
volume (BV/TV). Cortical parameters included total cross-sectional area, bone area, marrow 
area, cross-sectional moment of inertia, cortical thickness and tissue mineral density. 
Nomenclature is reported in accordance with suggested guidelines [16].
Mechanical Testing
Whole bone mechanical properties were assessed in four-point bending [17]. As opposed to 
three point bending which places large shear stresses at the single loading point, four-point 
bending produces pure bending between the two loading point allowing fracture to occur at 
the weakest location in this region due to bending [18]. The anterior surface of the each 
femur was placed on two lower supports with a span length of 9 mm and an upper span 
length of 3 mm. Specimens were loaded to failure at a rate of 2 mm/min, producing a force-
displacement curve for each sample. Structural properties (ultimate force, stiffness, 
displacement, energy absorption) were determined from the force-displacement curves. 
Apparent material properties were derived using cross-sectional moments of inertia and the 
distances from the centroid to the tensile surface using standard beam-bending equations for 
four-point bending. Yield points were defined using the 0.2% offset criterion. All 
mechanical analyses were performed using a custom MATLAB (Version 11) program [19].
Statistical Analysis
The 2×2 factor design (genotype × treatment) was assessed using a two-way ANOVA. Body 
weight values were assessed with a three-way ANOVA (genotype × treatment × time). When 
significant interactions were present (p ≤ 0.05) simple main effect analyses were conducted. 
All data are presented as means and standard deviations.
RESULTS
There was a significant effect of genotype on structural and mechanical material properties. 
B6 animals had significantly higher ultimate force, stiffness, and displacement at the 
structural level; tissue-level ultimate stress and modulus were significantly lower while total 
strain and toughness were significantly higher compared to A/J animals (Figure 1 and Table 
1). At the structural level, threre was no significant interaction on stiffness, yet a significant 
effect of drug with ZOL-treated animals being higher than VEH (p=0.0016). There was a 
significant drug × genotype interaction for ultimate force with both strains having 
significantly higher values in ZOL treated animals compared to VEH (A/J: +16%, p<0.001 
and B6: +30%, p<0.001). There was also a significant interaction for total displacement, 
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with no effect of ZOL in A/J but having a significant negative effect in B6 animals (A/J: 
−2%, p=0.82 and B6: −25%, p < 0.01).
Estimation of material properties based on bone geometry normalization revealed that the 
different response of the two mouse strains to ZOL treatment was due to both geometry and 
material properties (Figure 1 and Table 1). There was a significant yet similar effect of ZOL 
on ultimate stress in both genotypes compared to VEH-treated animals (A/J: +5%, p<0.001 
and B6: +14%, p<0.001). Modulus was not affected by ZOL in either genotype. Total strain, 
the material level equivalent of displacement, displayed a significant interaction with A/J 
animals being unaffected but with B6 animals showing significantly lower values with ZOL 
treatment (−23% compared to VEH; p = 0.0016).
All of the assessed cortical bone geometry variables were significantly different between 
genotypes (Table 2). Further, total cross-sectional area, bone area (Figure 2), and cross-
sectional moment of inertia were all affected similarly by ZOL in the two genotypes. There 
were no significant interactions for any of the cortical geometry variables (Table 2). B6 
animals had significantly higher cortical total cross-sectional area and cortical bone area 
compared to A/J animals (p<0.0001) and significantly lower tissue material density. ZOL 
did not alter cortical thickness or tissue material density in either strain but resulted in 
significantly higher cortical bone area in A/J animals by 8% (p=0.0001) and B6 animals by 
14% (p=0.0001). Animals within both genotypes had significantly higher trabecular bone 
volume/tissue volume (BV/TV) when treated with ZOL (Figure 3). A/J animals had a 207% 
higher BV/TV (p<0.0001) and B6 animals had a 100% higher BV/TV (p<0.0001) compared 
to VEH within genotype.
Three-way ANOVA (genotype, time, treatment) on body weight data revealed significant 
genotype and time effects but no significant treatment effects or interactions among any of 
the variables. B6 animals weighed significantly more than A/J animals at baseline (26.6 g vs 
25.4 g, respectively) and at the end of the experiment (28.5 g vs 26.8 g, respectively) and 
body weights were significantly higher at the end of the experiment than baseline.
DISCUSSION
Bisphosphonates play an important role in the management of osteoporosis and have been 
consistently shown to reduce fracture risk [20]. Several reports have shown that there are a 
small number of individuals that exhibit poor response to bisphosphonate treatment [2–8]. 
Potential explanations for this heterogeneous response include differences in patient 
compliance [21], underlying cause of bone loss/fracture risk, or intrinsic differences in the 
skeleton. Given the known continuum of geometric and material properties across 
individuals [9, 10] we aimed to test the hypothesis that zoledronate, one of several 
commonly used bisphosphonates, had different effects on bone mechanics in bones with 
disparate geometries/material properties. The results of this work, utilizing two commonly 
described inbred mouse strains (A/J and B6), support the hypothesis and suggest interactions 
between bone geometry/material properties and the response to zoledronate.
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We chose to study two commonly used inbred strains of mice, A/J and B6, due to their well-
described contrasting bone morphology and material properties [11–13]. Our VEH-treated 
animals confirmed previous work showing that A/J animals have bones with relatively low 
post-yield behavior while B6 animals have bones with higher post-yield properties (Figure 
1). The difference in post-yield properties between the genotypes is due in part to differences 
in the degree of mineralization arising from an intrinsic adaptive feature of the skeletal 
system to coordinately match material-level properties with bone external size to establish 
mechanical homeostasis across a population [11–13]. A similar coordinated regulation 
between bone external morphology and tissue-level mechanical properties has also been 
observed for human long bone [10, 22]. Despite differences in mineralization and geometry 
between the two mouse strains, the effects of zoledronate were quite similar for many 
parameters. Trabecular bone volume and mechanical properties such as ultimate force were 
higher in ZOL-treated animals compared to those treated with VEH within genotype. These 
represent clear benefits of zoledronate, confirming both previous animal work and the 
majority of clinical reports. Interestingly, although both genotypes responded similar to ZOL 
for trabecular bone, the response was actually 2× higher for A/J mice compared to B6 
(representing a significant interaction). The underpinnings of these different responses 
deserve more exploration.
The most distinct divergence in the response of the two genetic mouse strains was in bone 
displacement, specifically in the post-yield region, during mechanical testing. All measures 
of bone brittleness (total displacement, post-yield displacement, and total strain) displayed a 
significant interaction between genotype and drug treatment. VEH-treated B6 animals had 
higher values than VEH-A/J animals and while A/J animals were unaffected by zoledronate, 
B6 animals had significantly lower values with treatment. This reduction in post-yield 
displacement/strain represents an increase in tissue and structural brittleness. Previous work 
by our group and others have documented reductions, most specifically in post-yield 
properties, following bisphosphonate treatment (alendronate, risedronate, and zoledronate) 
[14, 23, 24].
Post-yield properties are known to be negatively affected by several tissue-level properties 
including mineralization [25], microdamage [26], collagen cross-linking [27], and hydration 
[28]. The absence of significant change in tissue-level density (from microCT) suggest some 
other tissue-level change – such as microdamage, collagen, or hydration – is likely playing a 
significant role in these B6 mice treated with zoledronate. Since, in our personal experience, 
microdamage is quite rare in mice without some external stimulus, altered hydration and/or 
collagen crosslinking are the lead candidates that will necessitate further exploration in B6 
mice treated with zoledronate.
There are several limitations to the current work. We utilized only one bisphosphonate, 
zoledronate, and thus do not know if this effect is common across the whole drug class. We 
also used a single dose and dosing schedule, as well as a single time point of assessment (8 
weeks of dosing). Our study utilized male mice with normal bone mass, building on 
previous work in these mouse strains; future studies will aim to study this strain/drug 
interaction in more clinically relevant models such as ovariectomized females. Finally, the 
mechanical testing of mouse bone violates assumptions of the beam bending equations used 
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in the calculations of parameters, although this is true of all papers describing the mechanics 
of mouse bone.
In conclusion we have documented genotype-specific mechanical property changes in 
response to zoledronate treatment. Understanding the underpinnings of these differences will 
be important to help determine if these effects are relevant to humans.
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Figure 1. 
Whole bone mechanical properties from femoral four-point bending. (A) Ultimate Force 
(Genotype p = 0.0001; Drug p = 0.0001; Interaction = 0.0021), (B) Stiffness (Genotype p = 
0.0001; Drug p = 0.0016; Interaction = 0.441), (C) Total Displacement (Genotype p = 
0.0001; Drug p = 0.0137; Interaction = 0.0304), (D) Ultimate Stress (Genotype p = 0.0001; 
Drug p = 0.0003; Interaction = 0.1779), (E) Modulus (Genotype p = 0.0001; Drug p = 
0.6261; Interaction = 0.9058), (F) Total Strain (Genotype p = 0.0001; Drug p = 0.0242; 
Interaction = 0.0217), * denotes a significant interaction between genotype and drug existed 
and within genotype there was a significant drug effect. All data presented as means and 
standard deviations.
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Figure 2. 
Cortical bone area of the femoral diaphysis. There was a significant main effect of genotype 
(B6 had higher bone area compared to A/J, p = 0.0001) and drug (zoledronate (ZOL) led to 
significantly higher bone area compared to vehicle (VEH), p = .0001). There was no 
significant interaction between variables (p = 0.076). Representative images (from the 
animal within each group closest to the group mean) of diaphyseal bone for each genotype/
drug condition are shown for comparison. All data presented as means and standard 
deviations.
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Figure 3. 
Distal femoral trabecular bone volume/tissue volume (BV/TV). There was a significant main 
effect of genotype (B6 had higher BV/TV compared to A/J, p = 0.001)) and drug 
(zoledronate (ZOL) led to significantly higher BV/TV compared to vehicle (VEH), p = 
0.0001). There was a significant interaction between genotype and drug (p = 0.0087) 
indicating that although both genotypes responded positively to ZOL, the response to was 
significantly greater in B6 compared to A/J. * denotes a significant interaction between 
genotype and drug existed and within genotype there was a significant drug effect. ** 
indicates that the ZOL effect was significantly greater for B6 than A/J. Representative 
images (from the animal within each group closest to the group mean) of distal femur bone 
for each genotype/drug condition are shown for comparison. All data presented as means 
and standard deviations.
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